Thibault Mazard
13PUBLICATIONS
53CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (13)
Sort by Publication Date:
|Jun 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.Jean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier
|Jun 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou
|Jul 27, 2024
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Auriane de Pellegars-Malhortie, Laurence Picque Lasorsa, Thibault Mazard
|Jul 10, 2024
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Antoine Adenis, François Ghiringhelli, Ludovic Gauthier
|Jun 17, 2024
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.Thibault Mazard, Caroline Mollevi, Evelyne M Loyer
|Feb 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study.Karl Bordeau, Morgan Michalet, Aïcha Keskes
Pageof 3
Frequent Collaborators
2 joint publications
Eric Assenat
2 joint publications
Thierry André
2 joint publications
Antoine Adenis
2 joint publications
Marc Ychou
2 joint publications
Morgan Michalet
2 joint publications
Karl Bordeau
1 joint publications
Bruno Pereira
1 joint publications
David Balayssac
1 joint publications
Alain R Thierry
1 joint publications
Aimery de Gramont
